Results 91 to 100 of about 4,101 (234)

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

eJHaem
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj   +1 more source

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, Volume 208, Issue 4, Page 1347-1358, April 2026.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

BTK‐Inhibition Enhances TLR‐7‐Mediated Interferon‐Alpha Production in pDCs by Blocking the Inhibitory BDCA‐2 Pathway [PDF]

In pDCs, BTK-inhibition (BTKi) blocks the IFN-α production via TLR-9, but not via TLR-7. Upon TLR-7 stimulation, BTKi enhances the production of IFN-α by blocking the inhibitory BDCA-2 pathway.
Boldrini, Vinicius, Ceglarek, Laura, Gerhards, Ramona, Meinl, Edgar, Peters, Anneli, Wichmann, Christian   +5 more
core   +1 more source

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

eLife
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph, Thomas E Wales, Sandrine Jayne, Robert G Britton, D Bruce Fulton, John R Engen, Martin JS Dyer, Amy H Andreotti   +7 more
doaj   +1 more source

498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.

Journal of Clinical and Translational Science
OBJECTIVES/GOALS: The research objectives of this project are to elucidate the effects of Bruton’s tyrosine kinase inhibitors (BTKi) of varying target specificity on platelet function with regard to platelet aggregation, adhesion, spreading, and ...
Thomas Kartika, Lorena Buitrago, Jihong Li, Barry S. Coller   +3 more
doaj   +1 more source

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

Biomarker Research
Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL).
Vivian Jiang, William Lee, Tianci Zhang, Alexa Jordan, Fangfang Yan, Qingsong Cai, Joseph McIntosh, Jovanny Vargas, Yang Liu, Michael Wang   +9 more
doaj   +1 more source

Whole Transcriptome Analysis of Aedes albopictus Mosquito Head and Thorax Post-Chikungunya Virus Infection

Pathogens, 2019
Chikungunya virus (CHIKV) is transmitted by Aedes mosquitoes and causes prolonged arthralgia in patients. After crossing the mosquito midgut barrier, the virus disseminates to tissues including the head and salivary glands.
Ravi kiran Vedururu, Matthew J. Neave, Vinod Sundaramoorthy, Diane Green, Jennifer A. Harper, Paul R. Gorry, Jean-Bernard Duchemin, Prasad N. Paradkar   +7 more
doaj   +1 more source

BTK Inhibitor Synergizes With CD19‐Targeted Chimeric Antigen Receptor‐T Cells in Patients With Relapsed or Refractory B‐Cell Lymphoma: An Open‐Label Pragmatic Clinical Trial

Cancer Medicine
Background CD19‐targeted chimeric antigen receptor‐T cell (CART19) therapy is clinically effective in patients with relapsed or refractory B‐cell lymphoma (BCL), but treatment failure and recurrence need to be overcome.
Wenjing Luo, Yinqiang Zhang, Chenggong Li, Jia Xu, Zhuolin Wu, Xindi Wang, Yun Kang, Danying Liao, Haiming Kou, Wei Xie, Wei Xiong, Jun Deng, Heng Mei, Yu Hu   +13 more
doaj   +1 more source

Risk of Invasive Fungal Infections in Patients with Chronic Lymphocytic Leukemia treated with Bruton Tyrosine Kinase Inhibitors – A Case-Control Propensity Score Matched Analysis [PDF]

Background: Prior reports have suggested a possible increase in the frequency of invasive fungal infections (IFIs) with use of a Bruton tyrosine kinase inhibitors (BTKi) for treatment of chronic lymphoid malignancies such as chronic lymphocytic leukemia (
Agudelo-Higuita, Nelson, Chastain, Daniel B., Henao Cordero, José, Henao-Martinez, Andres F., Lee, Alfred L.H., Sahra, Syeda, Scott, Brian, Tuells, José, Vargas Barahona, Lilian   +8 more
core   +1 more source

Denominació d'horitzons genètics (i capes) [PDF]

En aquest treball es presenta una proposta per a la denominació d'horitzons genètics dels sòls de Catalunya, recollint especialment el cas de la gènesi dels que s'han desenvolupat sobre materials originaris rics en carbonatats i guix.
Grup de Treball Nomenclatura d'Horitzons,
core